Business Context and Reporting Period
Company: U.S. Physical Therapy, Inc. (USPH)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025 (Third Quarter)
Business Overview: USPH operates two reportable segments: Physical Therapy Operations (outpatient clinics and home-care practices) and Industrial Injury Prevention (IIP) Services. As of September 30, 2025, the company owned or managed 779 clinics, an increase of 79 clinics from the prior year period.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Revenue | $197,132 | $168,033 | $578,264 | $490,898 |
| Gross Profit | $36,872 | $29,131 | $109,561 | $91,394 |
| Gross Margin | 18.7% | 17.3% | 18.9% | 18.6% |
| Operating Income | $25,330 | $12,847 | $69,910 | $43,343 |
| Net Income (Total) | $17,642 | $9,777 | $48,830 | $33,106 |
| Net Income Attributable to USPH | $13,138 | $6,628 | $35,430 | $22,180 |
| Diluted EPS (USPH) | $0.48 | $0.39 | $1.85 | $1.32 |
| Cash and Equivalents | $31,102 | $41,362 | $31,102 | $116,959 |
| Total Debt (Principal) | $160,988 | $154,578 | $160,988 | $154,578 |
| Adjusted EBITDA (Non-GAAP) | $23,855 | $21,071 | $70,256 | $59,966 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 17.3% in Q3 2025 and 17.8% for the nine months ended September 30, 2025, compared to the prior year. Growth was driven by the addition of 84 net owned clinics since the comparable prior year period.
- Profitability: Operating income surged 97.2% in Q3 2025, largely due to a $5.9 million gain from the change in fair value of contingent earn-out consideration, compared to a $1.9 million loss in the prior year.
- Acquisitions: The company completed several acquisitions in 2025, including a 60% interest in a three-clinic practice (July 2025) and a 40% interest in a home-care practice (April 2025). Total cash used for business purchases in the first nine months of 2025 was $15.2 million.
- Cash Flow: Operating cash flow decreased to $50.1 million for the nine months ended September 30, 2025, from $55.5 million in the prior year, primarily due to increased accounts receivable and timing of collections.
Guidance, Outlook, and Risks
- Dividends: The Board declared a quarterly dividend of $0.45 per share, payable December 12, 2025.
- Share Repurchase: A new share repurchase program was approved in August 2025, authorizing up to $25.0 million in repurchases through December 31, 2026. No shares were repurchased in the first nine months of 2025.
- Regulatory Environment: Medicare reimbursement rates decreased by approximately 2.9% for 2025. The company notes risks related to potential retroactive reductions in Medicare/Medicaid payments and changes in third-party payor policies.
- Debt and Liquidity: The company maintains a $325 million credit facility (maturity June 2027). As of September 30, 2025, $148.5 million was available under the revolving facility. The company is in compliance with all financial covenants.
- Non-GAAP Measures: Management utilizes Adjusted EBITDA and Operating Results to evaluate performance, excluding items such as contingent consideration changes, clinic closure costs, and equity-based compensation.
Investor Verification Checklist
- Contingent Consideration Volatility: Verify the impact of the $11.5 million gain on contingent earn-out consideration for the nine months ended September 30, 2025, on operating income stability.
- Redeemable Non-Controlling Interest (RNCI): Review the $277.7 million RNCI balance and the associated revaluation charges to retained earnings, which impact EPS but not GAAP net income.
- Acquisition Integration: Assess the integration costs and performance of recent acquisitions, particularly the Metro home-care practice and the July 2025 three-clinic acquisition.
- Medicare Reimbursement Trends: Monitor the impact of the 2.9% Medicare rate decrease for 2025 on the net rate per patient visit, which remained relatively flat at $105.54 in Q3 2025.
- Debt Servicing: Confirm the company's ability to service its $161 million debt load given the increase in interest rates (all-in effective rate of 5.6% for the nine months ended September 30, 2025).